An overview on anti-tubulin agents for the treatment of lymphoma patients

Barreca, Marilia; Stathis, Anastasios; Barraja, Paola; Bertoni, Francesco

doi:10.1016/j.pharmthera.2020.107552

Cited by 49 publications

(28 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, therapies targeting mitosis have been widely used in cancer for decades. Microtubules-targeting agents, which disrupt microtubule dynamics and block mitotic progression, are the most important antimitotic drugs used in the clinical treatment of both solid tumors and hematological malignancies [4,5]. However, the clinical utility of microtubules-targeting agents is limited due to severe adverse effects and drug resistance [6].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

et al. 2021

View full text Add to dashboard Cite

Polo-like kinase 4 (PLK4), a key regulator of centriole biogenesis, has recently been shown to play key roles in tumorigenesis. Blocking PLK4 expression by interference or targeted drugs exhibits attractive potential in improving the efficacy of chemotherapy. Nevertheless, the role of PLK4 in diffuse large B-cell lymphoma (DLBCL) is still undefined. In this study, we discover that PLK4 is a potential target for the treatment of DLBCL, and demonstrate the efficacy of a PLK4 inhibitor when used in combination with doxorubicin. Pharmaceutical inhibition of PLK4 with CFI-400945 inhibited DLBCL cell proliferation and induced apoptotic cell death. The anti-tumor effects were accompanied by mitotic defects, including polyploidy and cytokinesis failure. Activation of p53 and Hippo/YAP tumor suppressor signaling pathway was identified as the potential mechanisms driving CFI-400945 activity. Moreover, CFI-400945 treatment resulted in activation of DNA damage response. Combining CFI-400945 with doxorubicin markedly delayed tumor progression in DLBCL xenografts. Finally, PLK4 was increased in primary DLBCL tissues and cell lines. High levels of PLK4 expression were associated with poor survival in the patients receiving CHOP-based treatment, implicating PLK4 as a predictive biomarker of DLBCL chemosensitivity. These results provide the therapeutic potential of CFI-400945 both as monotherapy or in combination with doxorubicin for the treatment of DLBCL.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Currently, more than 80 active phase I-III clinical trials have been carried out to evaluate the efficacies of adcetris in cancers, but drug resistance has been reported in patients treated with adcetris. Strategies to overcome drug resistance and combinatory regimens to achieve maximal efficacy are being tested in lymphoma [89]. Adcetris is used in the clinic as a consolidation therapy after autologous stem cell transplantation (ASCT).…”

Section: Adcetris/brentuximab Vedotinmentioning

confidence: 99%

Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms

Yao

Jiang

2021

Marine Drugs

View full text Add to dashboard Cite

Worldwide, 19.3 million new cancer cases and almost 10.0 million cancer deaths occur each year. Recently, much attention has been paid to the ocean, the largest biosphere of the earth that harbors a great many different organisms and natural products, to identify novel drugs and drug candidates to fight against malignant neoplasms. The marine compounds show potent anticancer activity in vitro and in vivo, and relatively few drugs have been approved by the U.S. Food and Drug Administration for the treatment of metastatic malignant lymphoma, breast cancer, or Hodgkin′s disease. This review provides a summary of the anticancer effects and mechanisms of action of selected marine compounds, including cytarabine, eribulin, marizomib, plitidepsin, trabectedin, zalypsis, adcetris, and OKI-179. The future development of anticancer marine drugs requires innovative biochemical biology approaches and introduction of novel therapeutic targets, as well as efficient isolation and synthesis of marine-derived natural compounds and derivatives.

show abstract

“…More recent examples of natural products that have impacted medicine, and in particular oncology, are the taxane paclitaxel, first isolated from the bark of the Pacific yew tree Taxus brevifolia, and the vinca alkaloids (vincristine and vinblastine), obtained from the Madagascar periwinkle plant Catharanthus roseus. They alter the dynamic equilibrium of polymerization or depolymerization of microtubules, compromising the mitotic spindle apparatus and causing apoptosis after metaphase arrest [22]. Camptothecin, extracted from the Camptotheca acuminata tree [23], is effective against a broad spectrum of tumors by blocking DNA topoisomerase I (topo I) [24].…”

Section: Introductionmentioning

confidence: 99%

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

et al. 2020

Self Cite

View full text Add to dashboard Cite

The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve different pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year. Marine-based pharmaceuticals have started to impact modern pharmacology and different anti-cancer drugs derived from marine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.

show abstract

An overview on anti-tubulin agents for the treatment of lymphoma patients

Cited by 49 publications

References 182 publications

Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

Contact Info

Product

Resources

About